Description of event:
International Conference and Exhibition on Biowaivers and Biosimilars
Biosimilars-2012 is a remarkable event which brings together a unique and International mix of large and
medium Pharmaceutical and Biotech companies, leading universities and Pharmacological research institutions making the conference a perfect platform to share experience, foster collaborations across industry and academia, and evaluate emerging technologies across the globe.
The International Conference and Exhibition on Biowaivers and Biosimilars will schedule and coordinate all meetings with our Editorial Board Members and other experts in the
Pharmacology and Biotech field across the World. The scientific program paves a way to gather visionaries through the research talks and presentations and put forward many thought provoking strategies in Biowaivers and Biosimilars.
Conference highlights the following topics:
• Biosimilars
Pathway
• EU MAb Guidelines
• Skill Set for Biosimilars Development
• Biosimilar Therapeutics
•
Clinical Issues
• Reference Standards
• Guidelines for Marketing
•
In vitro &
In vivo Correlations
• Bioequivalence Testing
• Biowaivers
• Pharmaceutics
International Conference and Exhibition on Biowaivers and Biosimilars, having the theme "A Synergistic Approach towards Biowaivers & Biosimilars."
Biosimilars-2012 is comprised of 12 tracks and 67 sessions designed to offer comprehensive sessions that address
current issues in Biowaivers and Biosimilars.
Biosimilars: Innovator
Pharmaceutical Products
Track 1-1 Biosimilars: An overview
Track 1-2
Biotechnology medicinal products different from
drugs
Track 1-3 Future of next generation biosimilars
Track 1-4 Challenges faced in developing biosimilars
Track 2: Skill Set for Biosimilars Development
Track 2-1 Immunogenicity
Track 2-2
Clinical development
Track 2-3 Pharmacovigilance
Track 2-4 Biosimilars development
Track 2-5 Biomedical informatics
Track 2-6 Nanobiotechnology
Track 3: Biosimilars: Regulatory Approach
Track 3-1 Licensing of biosimilars
Track 3-2 Biosimilars regulation
Track 3-3 Patent filling
Track 3-4 FDA's view on biosimilars
Track 4:
Clinical Studies
Track 4-1
Clinical trials
Track 4-2 Risk
management and quality affairs
Track 4-3
Transgenic animals
Track 4-4 Targeted
cell line development
Track 4-5
Clinical PK/PD studies
Track 4-6
Toxicology
Track 4-7 Aspects of genotoxicity tests
Track 5: Biosimilars Therapeutics
Track 5-1
Recombinant blood products
Track 5-2
Recombinant vaccines
Track 5-3 Growth hormones
Track 5-4 Biosimilar
peptides
Track 5-5
Recombinant therapeutic proteins
Track 5-6 Biosimilars in
cancer treatment
Track 5-7 Biosimilars
monoclonal antibodies
Track 5-8 Biosimilar interferon
Contact us:
Conference Secretariat: Biosimilars-2012, OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake, Los Angeles, CA 91362-7354, USA
Email: biosimilars2012@omicsgroup.com